King Pharmaceuticals KG Legacy Reinsurance — Net loan receivable from related party

Similar metrics at other companies

ESQ

ESQRelated Party Loans Receivable

$0—

FCFLoans And Leases Receivable Related Parties

$31.57M+2.1%

SUI

SUIGLoans And Leases Receivable Related Parties

$0—

KRNYLoans And Leases Receivable Related Parties

$2.3M-4.2%

HBCPLoans And Leases Receivable Related Parties

$10.15M-10.5%

FUNCLoans And Leases Receivable Related Parties

$4M-15.1%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LoansAndLeasesReceivableRelatedParties.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's legacy reinsurance — net loan receivable from related party.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — net loan receivable from related party?: King Pharmaceuticals (KG) reported legacy reinsurance — net loan receivable from related party of $78.61M in Q1 2026.
What does legacy reinsurance — net loan receivable from related party mean?: Represents the outstanding balance of loans provided to affiliated entities within the Legacy Reinsurance segment. This metric reflects intercompany financing arrangements and the associated credit risk exposure to related parties.